SD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, introduced NOBIVAC® Myxo-RHD PLUS vaccine to reduce mortality and clinical signs of the three most common viral diseases in rabbitsi: myxomatosis and rabbit haemorrhagic disease (RHD) caused by both classic (RHDV1) and variant (RHDV2) strains. Rabbits have become increasingly popular as a companion animal and are now the fourth most popular pet in Europeii, after dogs, cats and birds. Rabbits are meticulously clean animals and are easy to housetrain. Also, much like a dog, a pet rabbit can be taught to respond to his/her name, sit in your lap, and do simple tricks.
“MSD Animal Health is proud to introduce NOBIVAC Myxo-RHD PLUS, the first and only single injection vaccine to protect pet rabbits against the three most common, and often fatal, viral diseases affecting rabbits, as part of our ongoing commitment to innovation that improves the health and welfare of animals,” said Ingrid Deuzeman, Global Lead Companion Animal Vaccines at MSD Animal Health. “With one vaccination, pet rabbits can now be protected against these diseases.”
Nobivac Myxo-RHD Plus is a vaccine used in rabbits to reduce death and clinical signs due to myxomatosis and rabbit haemorrhagic disease (RHD). Myxomatosis is caused by the myxoma virus and is spread between rabbits by close contact and biting insects such as fleas and mosquitoes. The virus causes swelling and discharge from the eyes, nose and bottom with most rabbits dying within 10 – 14 days. RHD, caused by classical RHD virus (RHDV1) and RHD type 2 virus (RHDV2), leads to blood clots in major organs such as the heart, lungs and kidneys leading to heart and respiratory failure when the heart and lungs do not work properly. Nobivac Myxo-RHD Plus contains live myxoma vectored RHD virus strains 009 and MK1899.
Features of Nobivac Plus Rabbit Vaccine
A live vaccine, as an aid in the prevention of myxomatosis and viral haemorrhagic disease in rabbits. This product may only be prescribed by your veterinary practitioner from whom advice must be sought. Product Information for Vets – Nobivac Myxo RHD Plus
Vaccine for use in rabbits against myxomatosis and haemorrhagic disease (caused by Classic and Variant (Type 2) strains) containing per dose of reconstituted vaccine:
Live myxoma vectored RHD virus strain 009: 103.0 – 105.8 FFU*
Live myxoma vectored RHD virus strain MK1899: 103.0 – 105.8 FFU*
*Focus Forming Units
For uses, dosage, contra-indications and warnings please consult your prescribing vet or the summary of product characteristics. Further information is available on request. Use medicines responsibly.
Benefits of Nobivac Plus Rabbit Vaccine
obivac Myxo-RHD PLUS will make vaccination more convenient, helping improve levels of compliance against variant strains of RHD which is currently estimated to be at around only 60 percent of the vaccinated rabbit population. A single low volume 0.5ml vaccination provides 12 months of duration of immunity against all three pathogens. Available in a pack of five, single dose vials, with a shelf-life of two years, the vaccine can be used from the age of five or seven weeks onwards to achieve the full duration of immunity. Immunity is provided within three weeks of administration
Direction for use
Nobivac Myxo-RHD Plus is available as a freeze dried powder (lyophilisate) and solvent for suspension for injection and can only be obtained with a prescription. It is given to rabbits from five weeks of age as a single injection under the skin. Protection starts at three weeks and lasts for one year. Rabbits need to be revaccinated every year. For more information about using Nobivac Myxo-RHD Plus, see the package leaflet or contact your veterinarian or pharmacist.
A transient temperature increase of 1 – 2°C can commonly occur. A small, non-painful swelling (maximum 2 cm diameter) at the injection site is commonly observed within the first two weeks after vaccination. The swelling will resolve completely by 3 weeks after vaccination. In pet rabbits, local reactions at the injection site such as necrosis, scabs, crusts or hair loss may occur in very rare cases. Serious hypersensitivity reactions, which may be fatal, may occur after vaccination in very rare cases. The appearance of mild clinical signs of myxomatosis may occur within 3 weeks of vaccination in very rare cases. Recent or latent infection with field myxoma virus seems to play a role in this to a certain extent.The frequency of adverse reactions is defined using the following convention:− very common (more than 1 in 10 animals treated displaying adverse reaction(s))− common (more than 1 but less than 10 animals in 100 animals treated)− uncommon (more than 1 but less than 10 animals in 1,000 animals treated)− rare (more than 1 but less than 10 animals in 10,000 animals treated)− very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Prices of Nobivac Plus Rabbit Vaccine